Patents Examined by Elli Peselev
  • Use of 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives in leukemia management
    Patent number: 8841319
    Abstract: The present invention relates to the use of a compound of formula (I) wherein R1 is H, C1-C6-alkyl, phenyl-C1-C4-alkyl or phenyl, R2 is a phenyl group which is substituted with 2 or 3 C1-C6-alkoxy groups and R3 is indolyl or azaindolyl which may carry one or two substituents independently selected from C1-C6-alkyl, C1-C6-alkoxy, phenyl, OH, halogen, NH2, C1-C6-alkylamino, di-C1-C6-alkylamino, heteroaryl with 5 or 6 ring atoms containing 1 or 2 heteroatoms which are independently selected from O, N, and S, or heterocyclyl with 5 or 6 ring atoms containing 1 or 2 heteroatoms which are independently selected from O, N, and S, a physiologically acceptable salt thereof, or a solvate of the compound of formula (I) or of the salt thereof, for the prevention or treatment of leukemia.
    Type: Grant
    Filed: December 4, 2008
    Date of Patent: September 23, 2014
    Assignee: Johannes Gutenberg-Universitat Mainz
    Inventors: Gerd Dannhardt, Thomas Fischer, Florian Heidel
  • 2?-fluorine-4?-substituted-nucleoside analogues, preparation methods and uses thereof
    Patent number: 8835615
    Abstract: The present invention provides 2?-fluorine-4?-substituted-nucleoside analogs or their pro-drugs or 5?-phosphate esters (including the pro-drugs of the 5?-phosphate esters), preparation methods and uses thereof. The compounds have the general formula as follows: wherein: The compounds are used in the synthesis of drugs for the treatment of virus infection, especially for the treatment of HBV, HCV or HIV infection.
    Type: Grant
    Filed: June 27, 2008
    Date of Patent: September 16, 2014
    Inventor: Junbiao Chang
  • Macrocyclic lactone tablet formulation
    Patent number: 8835397
    Abstract: The invention relates to a table formulated for administration to an animal to treat parasite infestation. The tablet includes at least one macrocyclic lactone compound with anthelmintic activity dissolved in at least one organic solvent and subsequently formulated into a tablet. The tablets produced have a high degree of stability when stored over time and also provide the animal with a dose of agent sufficient to be therapeutically effective.
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: September 16, 2014
    Assignee: Bayer New Zealand Ltd.
    Inventors: Karthigeyan Nanjan, Fadil Al Alawi, Wayne Frederick Leech, Man Yik Li, Steve Li
  • Sulfated oligosaccharide derivatives
    Patent number: 8828952
    Abstract: The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment of a mammalian subject.
    Type: Grant
    Filed: October 16, 2008
    Date of Patent: September 9, 2014
    Assignee: Progen Pharmaceuticals Limited
    Inventors: Vito Ferro, Tomislav Karoli, Ligong Liu, Paul Newton Handley, Kenneth David Johnstone, Norbert Wimmer, Edward Timothy Hammond
  • Topical application of ivermectin for the treatment of dermatological conditions/afflictions
    Patent number: 8815816
    Abstract: Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: August 26, 2014
    Assignee: Galderma S.A.
    Inventors: Vincent Manetta, Gary R. Watkins
  • Methods of regulating actin cytoskeletal rearrangement and intercellular gap formation
    Patent number: 8809303
    Abstract: Methods are described for reducing cytoskeletal rearrangement and intercellular gap formation by contacting cells with an aminoalkyl glucosaminide phosphate. In particular, the methods can be used to reduce actin cytoskeletal rearrangement and/or intracellular gap formation related to ischemic or ischemia-reperfusion events and to alleviate diseases or conditions related to increased actin cytoskeletal rearrangement.
    Type: Grant
    Filed: April 9, 2009
    Date of Patent: August 19, 2014
    Assignee: The University of North Carolina at Chapel Hill
    Inventor: Thomas Michael Egan
  • Rehydratable polysaccharide particles and sponge
    Patent number: 8802652
    Abstract: Tissue and other body structures may be protected using a hydrated composition made from free-flowing substantially collagen-free rehydratable polysaccharide particles and rehydratable polysaccharide sponges. Rehydration of the particles without clumping may be carried out be dispersing the particles in a biocompatible water-miscible polar dispersant such as ethanol and combining the dispersion with sufficient aqueous solvent for the particles to convert them to a cohesive hydrogel. The hydrated composition may assist in returning an injured, inflamed or surgically repaired surface to a normal state, e.g., through one or more healing mechanisms such as modulation of an inflammatory response, phagocytosis, mucosal remodeling, reciliation or other full or partial restoration of normal function.
    Type: Grant
    Filed: April 23, 2009
    Date of Patent: August 12, 2014
    Assignee: Medtronic, Inc.
    Inventors: Matthew Franco Myntti, Dana A. Oliver, Brian Vaccaro
  • Methods of using human milk oligosaccharides for improving airway respiratory health
    Patent number: 8802650
    Abstract: Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to preterm infants, term infants, toddlers, and children for improving airway defense mechanisms.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: August 12, 2014
    Assignee: Abbott Laboratories
    Inventors: Rachael Buck, Geralyn O. Duska-McEwen, Steven R. Davis
  • Methods for treating resistant diseases using triazole containing macrolides
    Patent number: 8796232
    Abstract: Triazole-containing macrolide and ketolide antibiotics, therapeutic compositions containing them and methods of use for treating diseases caused by one or more resistant organisms are described.
    Type: Grant
    Filed: October 24, 2009
    Date of Patent: August 5, 2014
    Assignee: Cempra Pharmaceuticals, Inc.
    Inventors: Prabhavathi B. Fernandes, David E. Pereira
  • Methods for treating gastrointestinal diseases
    Patent number: 8791080
    Abstract: Described herein are macrolide and ketolide antibiotics and pharmaceutical compositions, methods, and uses thereof for treating gastrointestinal diseases.
    Type: Grant
    Filed: October 24, 2009
    Date of Patent: July 29, 2014
    Assignee: Cempra Pharmaceuticals, Inc.
    Inventor: Prabhavathi B. Fernandes
  • Glycoproteins and glycosylated cells and a method for the preparation of the same
    Patent number: 8785594
    Abstract: The present application discloses novel glycoproteins and a related glycosylcarbamoylation methodology suitable for the preparation of glycopeptides (in particular glycoproteins and glycosylated cells), as well as the use of such glycoproteins in medicine, e.g. as pharmaceuticals and diagnostics or in diagnostic kits. A method for the preparation of a carbohydrate-peptide conjugate includes reacting a cyclic carbamate with a peptide which has at least one primary amino group.
    Type: Grant
    Filed: September 24, 2008
    Date of Patent: July 22, 2014
    Assignee: Glycom A/S
    Inventors: Gyula Dekany, Károly Ágoston, István Bajza, Marie Bøjstrup, Lars Kröger
  • Stabilized and lyophilized formulation of anthracycline compounds
    Patent number: 8785406
    Abstract: The present invention provides a lyophilized amrubicin formulation and a process thereof. In the process, the concentration of the aqueous solution before lyophilization is controlled to about 7.5 mg(potency)/mL or more. Thus, the formulation decreases the production of desaccharified compound and is stable to storage for a long period. The formulation is useful as a cancer chemotherapeutic agent.
    Type: Grant
    Filed: May 27, 2009
    Date of Patent: July 22, 2014
    Assignee: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Hajimu Hirofuji, Hotaka Hashimoto, Kazunari Tanaka
  • Levoisovalerylspiramycin I, II or III, preparations, preparation methods and uses thereof
    Patent number: 8778896
    Abstract: Disclosed are levoisovalerylspiramycin I, II or III, preparations, preparing methods and uses thereof. The preparations comprise levoisovalerylspiramycin I, II or III and pharmaceutically acceptable carrier and/or adjuvant, wherein the purity of levoisovalerylspiramycin I, II or III is above 90 wt %. The levoisovalerylspiramycin I, II or III has a good antibacterial activity, and the preparations include solution for injection, powder for injection or lyophilized powder for injection.
    Type: Grant
    Filed: May 25, 2011
    Date of Patent: July 15, 2014
    Assignee: Shenyang Tonglian Group Co., Ltd.
    Inventors: Yang Jiang, Yuyou Hao
  • Lactulose for bowel evacuation
    Patent number: 8778907
    Abstract: A method of treating an adult patient in need of bowel evacuation via the administration of one or more doses of a bowel evacuant consisting of a total of from about 180 g to about 220 g of lactulose in a dosing regimen suitable to achieve bowel evacuation prior to a diagnostic, therapeutic or surgical procedure is disclosed.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: July 15, 2014
    Assignee: Cumberland Pharmaceuticals
    Inventors: Leo Pavliv, Bryan Voss
  • Cystitis treatment with high dose chondroitin sulfate
    Patent number: 8778908
    Abstract: Interstitial cystitis and related GAG-deficient conditions of the bladder and urinary tract are treated by instillation of high dose chondroitin sulfate, such as 400 mg/20 mL. The higher dose of chondroitin is effective for the rapid reduction of symptoms, particularly in patients with severe and otherwise recalcitrant cystitis.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: July 15, 2014
    Assignee: Stellar International Inc.
    Inventors: Peter R. Riehl, Sungtack Samuel Hahn
  • Aureolic acid derivatives, the method for preparation thereof and the uses
    Patent number: 8772253
    Abstract: Aureolic acid derivatives, process for obtaining them and uses thereof. This invention provides a bacterial strain that produces compound belonging to the family of aureolic acids useful in the treatment of cancer or nervous system diseases.
    Type: Grant
    Filed: July 14, 2010
    Date of Patent: July 8, 2014
    Assignee: Entrechem, S.L.
    Inventors: Luz Elena Núñez González, Nuria Menéndez Sánchez, Javier González Sabin, Francisco Moris Varas, Beatriz García Fernández, Maria Pérez Solares, Alfredo Fernández Braña, Maria del Carmen Méndez Fernández, José Antonio Salas Fernández
  • Steroid compound
    Patent number: 8765696
    Abstract: A steroid compound of the Formula (1): [wherein R1 represents a group selected from the group consisting of H, CH3, C2H5, C3H7 and CH (CH3)2, R2 represents a group selected from NH2, NHAc and OCOR1, R3 represents a group selected from the group consisting of CH3, COOCH3 and CH2OCOR1.
    Type: Grant
    Filed: March 8, 2010
    Date of Patent: July 1, 2014
    Assignee: Mikasa Seiyaku Co., Ltd.
    Inventor: Takayuki Ishii
  • Pesticide compositions exhibiting enhanced activity
    Patent number: 8765697
    Abstract: Pest controlling compositions exhibiting enhanced pesticidal activity levels are disclosed. In one embodiment, a composition includes at least one pesticide, at least one proteinaceous material and at least one polymeric material. In this embodiment, the composition exhibits enhanced pesticidal activity levels compared to a composition dissimilar only in not having the at least one proteinaceous material and the at least one polymeric material. Still, alternative embodiment pesticide compositions exhibiting enhanced activity levels are disclosed.
    Type: Grant
    Filed: April 27, 2010
    Date of Patent: July 1, 2014
    Assignee: Dow AgroSciences, LLC.
    Inventors: Stephen L. Wilson, Lei Liu, James D. Thomas, Raymond E. Boucher, Jr., James E. Dripps, Margaret S. Kempe
  • Method of inhibiting premature aging of human skin caused by exposure to infrared radiation
    Patent number: 8765693
    Abstract: A method of inhibiting premature aging of human skin caused by exposure to infrared radiation comprising contacting the skin with a composition containing a therapeutically-effective amount of at least one protective compound chosen from baicalin, phloretin and neohesperidin dihydrochalcone, as well as combinations thereof.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: July 1, 2014
    Assignee: L'Oreal
    Inventors: Anthony Potin, Christian Oresajo, Nannan Chen, Donna McCann
  • Compositions and methods for increasing telomerase activity
    Patent number: 8759304
    Abstract: The present invention relates to methods and compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical, including topical, and nutraceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient, such as, for example, HIV infection, various degenerative diseases, and acute or chronic skin ailments. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and proliferation of stem cells.
    Type: Grant
    Filed: March 5, 2010
    Date of Patent: June 24, 2014
    Assignee: Telomerase Activation Science, Inc.
    Inventors: Calvin Bruce Harley, Allison C. Chin, Tsutomu Akama, Nancy Yuk-yu Ip, Yung-hou Wong, David M. Miller-Martini